Perivascular inflammation is a prominent pathologic feature in most animal models of
pulmonary hypertension (PH) as well as in pulmonary arterial hypertension (PAH) patients …

Background: Right ventricular (RV) adaptation to acute and chronic pulmonary hypertensive
syndromes is a significant determinant of short-and long-term outcomes. Although …

Pulmonary hypertension (PH) encompasses a syndrome of diseases that are characterized
by elevated pulmonary artery pressure and pulmonary vascular remodeling and that …

Background—Vascular occlusion and complex plexiform lesions are hallmarks of the
pathology of severe pulmonary arterial hypertension (PAH) in patients. However, the …

Pulmonary arterial hypertension (PAH) is no longer an orphan disease. There are three
different classes of drugs for the treatment of PAH that are currently being used and an …

Pulmonary hypertension is a complex, progressive condition arising from a variety of genetic
and pathogenic causes. Patients present with a spectrum of histologic and …

Hypoxic pulmonary hypertension (PH) comprises a heterogeneous group of diseases
sharing the common feature of chronic hypoxia-induced pulmonary vascular remodeling …

Pulmonary hypertension (PH) because of chronic lung disease is categorized as Group 3
PH in the most recent classification system. Prevalence of these diseases is increasing over …

Pulmonary hypertension (PH) is a progressive cardiopulmonary disease characterized by
pulmonary arterial remodeling. Clonal somatic mutations including JAK2 V617F, the most …

Background: Endothelial dysfunction enhances vascular inflammation, which initiates
pulmonary arterial hypertension (PAH) pathogenesis, further induces vascular remodeling …